Historical approach to the discovery of meprobamate and its introduction in psychiatry: Half-century of anxiety drug treatment;Aproximación histórica al descubrimiento del meprobamato y su introducción en psiquiatría: Medio siglo de terapéutica ansiolítica

Archivos de Psiquiatria

Volumn 68, Issue 2, 2005, Pages 103-122

  López Muñoz, Francisco ^a   Ramchandani, Dilip ^b   Alamo, Cecilio ^a   Cuenca, Eduardo ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Anxiety; Anxiolytic drugs; History of psychiatry; Meprobamate; Psychopharmacology

Indexed keywords

2 PHENOXYETHANOL; BENZODIAZEPINE; MEPHENESIN; MEPROBAMATE;

ANTICONVULSANT ACTIVITY; ANTIMICROBIAL THERAPY; ANXIETY DISORDER; CLINICAL RESEARCH; DRUG ABUSE; DRUG APPROVAL; DRUG DEPENDENCE; DRUG MECHANISM; DRUG OVERDOSE; DRUG SYNTHESIS; DRUG TOLERANCE; FOOD AND DRUG ADMINISTRATION; HISTORY OF MEDICINE; HUMAN; MUSCLE RELAXATION; NEUROSIS; PSYCHOANALYSIS; PSYCHOPHARMACOLOGY; REVIEW; SEDATION; TRANQUILIZING ACTIVITY;

EID: 23144461309     PISSN: 15760367     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Alamo C, López-Muñoz F, Echániz T, Cuenca E. Fármacos ansiolíticos, sedantes e hipnóticos. En: López-Muñoz F, Alamo C, editores. Historia de la neuropsicofarmacología. Una nueva aportación a la terapéutica farmacológica de los trastornos del Sistema Nervioso Central. Madrid: Ediciones Eurobook S.L. y Servicio de Publicaciones de la Universidad de Alcalá; 1998. p. 245-68.
2. Pichot P. History of the treatment of anxiety. En: Noyes R, Roth M, Burrows GD, editors. Handbook of Anxiety. Vol. 4. The Treatment of Anxiety. Amsterdam: Elsevier Science Publishers; 1990. p. 3-25.
3. Eysenck HJ. The effects of psychotherapy: an evaluation. J Consul Psychol. 1952;16:319-324.
4. Hollister LE. The pre-benzodiazepine era. J Psychoactive Drugs. 1983;15:9-13.
5. Lehmann HE. Before they called it psychopharmacology. Neuropsychopharmacology. 1993;8:291-303.
6. Shorter E. A history of psychiatry. From the Era of the Asylum to the Age of Prozac. New York: John Wiley & Son Inc.; 1997.
7. Healy D. The Creation of Psychopharmacology. Cambridge: Harvard University Press; 2002.
8. Griesinger W. Die Pathologie und Therapie der psychischen Krankheiten. Stuttgart: Krabbe; 1867.
9. Woodward SB. Observations on the medical treatment of insanity (1846). Am J Psychiatry. 1994;151Supl 6:220-30.
10. Norton A. Depression. BMJ. 1979;2:429-30.
11. Liebreich O. Das Chloralhydrat ein neues Hypnoticum und Anästheticum, und desen Anwendung in die Medizin. Eine Arzneimittel- Unterssuchung. Berlin: Muller; 1869.
12. Linde OK. Pharmakopsychiatrie im Wandel der Zeit. Klingenmünster: Titia-Verlag; 1988.
13. Sourkes TL. Early clinical neurochemistry of CNS-active drugs. Chloral hydrate. Mol Chem Neurophath. 1992;17:21-30.
14. Locock C. Comment in discussion of Edward H. Sieveking, Analysis of fifty-two cases of epilepsy. Lancet. 1857;2:136-8.
15. Petit W. Du bromure de potassium dans les maladies nerveuses. Prog Med. 1891;19:177-8.
16. McLeod N. The hormone sleep: a new departure in the treatment of acute mania. BMJ. 1990;1:134-6.
17. Balme R. Early medicinal uses of bromides. J Royal College Physicians. 1976;10:205-8.
18. Cervello V. Sull'azione fisiologica della paraldeide e contributio allo studio del cloralio idrato. Ricerche. Arch Sc Med. 1882;6:177-214.
19. Fisher E, von Mering J. Uber ein neue Klasse von Schlafmitteln. Therapie Gegenwart. 1903;44:97-101.
20. Johns MW. Self-poisoning with barbiturates in England an Wales during 1959-74. BMJ. 1977;i:1.128-30.
21. Cossa P. Thérapeutiques neurologiques et psychiatriques. Paris: Masson; 1945.
22. Caldwell AE. History of psychopharmacology. En: Clark WG, Del Giudice J, editors. Principles of Psychopharmacology. New York: Academic Press; 1970. p. 9-30.
23. Jacobsen E. The early history of psychotherapeutic drugs. Psychopharmacology. 1986;89:138-44.
24. Ayd FJ. The early history of modern psychopharmacology. Neuropsychopharmacology. 1991;5:71-84.
25. Frankenburg FR. History of the development of antipsychotic medication. Psychiatr Clin North Am. 1994;17:531-40.
26. López-Muñoz F, Alamo C, Cuenca E. La «Década de Oro» de la psicofarmacología (1950-1960): trascendencia histórica de la introducción clínica de los psicofármacos clásicos, Psiquiatria.com (electronic journal), Sep, 4 (3), URL: http://www.psiquiatria.com/psiquiatria/revista/47/1800/? ++interactivo, 2000.
27. Ban TA. Pharmacotherapy of mental illness. A historical analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:709-27.
28. López-Muñoz F, Alamo C, Cuenca E. Aspectos históricos del descubrimiento y de la introducción clínica de la clorpromazina: medio siglo de psicofarmacología. Frenia. 2002;II(1):77-107.
29. López-Muñoz F, Alamo C, Rubio G, Cuenca E. Half a century since the clinical introduction of chlorpromazine and the birth of modern psychopharmacology. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:205-8.
30. Berger FM, Bradley W. The pharmacological properties of a, b-dihydroxy-g-(2-methylphenoxy)-propane (Myanesin). Br J Pharmacol. 1946;1:265-72.
31. Berger FM. Anxiety and the discovery of the tranquilizers. En: Ayd FJ, Blackwell B, editors. Discoveries in Biological Psychiatry. Baltimore: Ayd Medical Communications; 1984. p. 115-29.
32. Gilberts A, Descomps R. Le phénoxypropanediol. Comp Ren Soc Biol. 1910;69:145-7.
33. Mallison FB. A new synthetic curarising agent in anaesthesia. Lancet. 1947;1:98-100.
34. Berger FM. Mode of action of Myanesin. Br J Pharmacol. 1947;2:241.
35. Ludwig BJ, Piech EC. Some anticonvulsant agents derived from 1,3-propanediol. J Am Chem Soc. 1951;73:5.779-81.
36. Berger FM. The anticonvulsant activity of carbamate esters of certain of 2,2-disubstituted-1,3-propanediols. J Pharmacol Therap. 1952;104:229.
37. Selling LS. Clinical study of a new tranquilizing drug: use of Miltown (2-methyl-2-n-propyl-1,3,-propanediol dicarbonate). JAMA. 1955;157:1.594-6.
38. Borrus JC. Study of effects of Miltown (2-methyl-2-n-propyl-1,3,- propanediol dicarbonate). JAMA. 1955;157:1.594-6.
39. Fabing HD. Frenquel a blocking agent against experimental LSD-25 and mescaline psychosis. Preliminary note on its clinical application. Neurology. 1955;5:319.
40. Sarró R, Obiols J. Meprobamato en ansiedad. Med Clin (Barc). 1957;28(2):70.
41. Berger FM. Meprobamate and other agents used in mental disorders. Ann NY Acad Sci. 1957;67:671-894.
42. Farrar GE. Milestones in clinical pharmacology. Psychopharmacology. Depression and anxiety. Clin Ther. 1991;13:521-4.
43. Smith MC. Small Confort: A History of the Minor Tranquillizers. New York: Praeger Scientific; 1985.
44. Perelman SJ. The Road to Miltown. New York: Simon and Schuster; 1957.
45. Berger FM. As I remember. En: Ban TA, Healy D, Shorter E, editors. The Rise of Psychopharmacology and the Story of CINP. Budapest: Animula Publishing House; 1998. p. 59-62.
46. Laties VG, Weiss B. A critical review of the efficacy of meprobamate (Miltown, Equanil) in the treatment of anxiety. J Chr Dis. 1958;7:500-19.
47. Estes JW. The road to tranquillity: the search for selective anti-anxiety agents. Synapse. 1995;21:10-20.
48. Greenblatt DJ, Shader RI. Meprobamate: a study of irrational drug use. Am J Psychiatry. 1971;127:1.297-303.
49. López-Muñoz F, Alamo C, Cuenca E. El nacimiento de la era ansiolitica: Frank M. Berger y el desarrollo del meprobamato. JANO (Psiquiatria y Humanidades). 1999;I(2):13-4.
50. Cohen IM. The benzodiazepines. En: Ayd FJ, Blackwell B, editors. Discoveries in Biological Psychiatry. Baltimore: Ayd Medical Communications; 1984. p. 130-41.
51. Eison MS, Eison AS. Buspirone as a midbrain modulator: anxiolitics unrelated to traditional benzodiazepine mechanism. Drug Dev Res. 1984;4:109-19.
52. Bein HJ. Biological research in the pharmaceutical industry with reserpine. En: Ayd FJ, Blackwell B, editors. Discoveries in Biological Psychiatry. Baltimore: Ayd Medical Communications; 1984. p. 142-54.
53. De Quincey T. Confessions of an English Opium Eater. London Magazine; 1821.
54. López-Muñoz F, Alamo C, Cuenca E. Aportación de la clorpromazina al desarrollo de la psiquiatria. Archivos de Psiquiatria. 2003;66:15-34.
55. Gorman JM. New molecular targets for antianxiety interventions. J Clin Psychiatry. 2003;64 Supl 3:28-35.
56. Reul J, Holsboer F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol. 2002; 2:23-33.
57. Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviours. Annu Rev Pharmacol Toxicol. 2004;44:525-57.